DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Sweden
  • /
  • Healthcare
Author Program NEWCreate Narrative
CRAD B logo

C-Rad AB (publ) Stock Price

OM:CRAD B Community·SEK 1.2b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

CRAD B Share Price Performance

SEK 35.30
3.75 (11.89%)
​
SEK 45.00
Fair Value
SEK 35.30
3.75 (11.89%)
21.6% undervalued intrinsic discount
SEK 45.00
Fair Value
Price SEK 35.30
AnalystConsensusTarget SEK 45.00
Mon, 20 Jul 26
Fair ValueSEK 45.00
Share Pricen/a

CRAD B Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value SEK 45 21.6% undervalued intrinsic discount

Aging Population And Healthcare Digitization Will Expand Radiotherapy Demand

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
CRAD B logo
C-Rad
21.6% undervalued intrinsic discount

Aging Population And Healthcare Digitization Will Expand Radiotherapy Demand

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 20 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
CRAD B logo

CRAD B: New Radiotherapy Partnership Will Support A More Positive Outlook

Fair Value: SEK 45 21.6% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet and undervalued.

1 Risk
4 Rewards
View Full Analysis

C-Rad AB (publ) Key Details

SEK 444.4m

Revenue

SEK 110.0m

Cost of Revenue

SEK 334.4m

Gross Profit

SEK 284.6m

Other Expenses

SEK 49.9m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 22, 2026
1.48
75.26%
11.22%
0%
View Full Analysis

About CRAD B

Founded
2004
Employees
98
CEO
Tomas Blomquist
WebsiteView website
c-rad.com

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating; and Sentinel 4DCT, a laser-based optical surface scanning system. It also provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; and visual coaching solutions used for prospective and retrospective radiotherapy. In addition, the company offers cAutoVerify, an automation solution for the imaging suite and treatment room, automating patient identity validation, and accessory tracking. Further, it provides HIT1, HIT3, and HIT5 patient positioning laser, as well as laser positioning products and solutions. Additionally, the company offers support and training services; and service contracts. C-Rad AB (publ) was incorporated in 2004 and is headquartered in Uppsala, Sweden.

Recent CRAD B News & Updates

Analysis Article • Jul 24

C-Rad (STO:CRAD B) Strong Profits May Be Masking Some Underlying Issues

The market for C-Rad AB (publ)'s ( STO:CRAD B ) stock was strong after it released a healthy earnings report last week...
Analysis Article • Jul 21

C-Rad AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

C-Rad AB (publ) ( STO:CRAD B ) just released its latest quarterly results and things are looking bullish. It was...
User avatar
Narrative Update • Jul 20

CRAD B: New Radiotherapy Partnership Will Support A More Positive Outlook

Analysts have raised their price target for C-Rad from SEK 36 to SEK 45, citing updated assumptions about fair value, discount rate, revenue growth and profit margins in their models. What’s in the News for C-Rad C-Rad AB and SeeTreat Pty Ltd announced a partnership focused on more connected, intelligent and patient centric radiotherapy workflows.

Recent updates

No updates

C-Rad AB (publ) Competitors

GETI B logo

Getinge

Symbol: OM:GETI B
Market cap: SEK 64.2b
SECT B logo

Sectra

Symbol: OM:SECT B
Market cap: SEK 55.3b
MCOV B logo

Medicover

Symbol: OM:MCOV B
Market cap: SEK 35.8b
ASKER logo

Asker Healthcare Group

Symbol: OM:ASKER
Market cap: SEK 27.5b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide